{
  "variants": [
    {
      "variant": "LRRK2 Y1699C",
      "steps": {
        "step1": {
          "judgment": "Yes",
          "reason": "The paper explicitly states that LRRK2 mutations (e.g., Y1699C) are associated with Parkinson's disease and that wild-type LRRK2 enhances oxidative stress tolerance via the ERK pathway."
        },
        "step2": {
          "judgment": "Yes",
          "reason": "The assay (cell viability under oxidative stress) directly models the disease mechanism (oxidative stress and MAPK pathway dysfunction)."
        },
        "step3a": {
          "judgment": "No",
          "reason": "While wild-type (normal) and mutant (abnormal) controls are used, the paper does not explicitly mention replicates or statistical validation of results."
        },
        "step3b": {
          "judgment": "No",
          "reason": "The paper does not cite prior validation of the assay (e.g., no references to established methods) or mention commercial kits. The assay is not explicitly labeled as 'standard' in the literature."
        },
        "step3c": {
          "judgment": "No",
          "reason": "No known pathogenic/benign variants are explicitly used as controls in the study."
        },
        "step4a": {
          "judgment": "No",
          "reason": "No OddsPath values or statistical analyses (e.g., p-values, confidence intervals) are reported for Y1699C."
        },
        "step4b": {
          "judgment": "No",
          "reason": "The study does not quantify the number of benign/pathogenic controls used, making it impossible to assess strength."
        },
        "step4c": {
          "judgment": "N/A",
          "reason": "No OddsPath values are provided, and statistical analyses are insufficient."
        },
        "evidence_strength": "N/A"
      }
    },
    {
      "variant": "LRRK2 G2019S",
      "steps": {
        "step1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links G2019S to Parkinson's disease and its role in MAPK pathway dysfunction."
        },
        "step2": {
          "judgment": "Yes",
          "reason": "The assay (cell viability under oxidative stress) directly models the disease mechanism (oxidative stress and MAPK pathway dysfunction)."
        },
        "step3a": {
          "judgment": "No",
          "reason": "While wild-type (normal) and mutant (abnormal) controls are used, the paper does not explicitly mention replicates or statistical validation of results."
        },
        "step3b": {
          "judgment": "No",
          "reason": "The paper does not cite prior validation of the assay (e.g., no references to established methods) or mention commercial kits. The assay is not explicitly labeled as 'standard' in the literature."
        },
        "step3c": {
          "judgment": "No",
          "reason": "No known pathogenic/benign variants are explicitly used as controls in the study."
        },
        "step4a": {
          "judgment": "No",
          "reason": "No OddsPath values or statistical analyses (e.g., p-values, confidence intervals) are reported for G2019S."
        },
        "step4b": {
          "judgment": "No",
          "reason": "The study does not quantify the number of benign/pathogenic controls used, making it impossible to assess strength."
        },
        "step4c": {
          "judgment": "N/A",
          "reason": "No OddsPath values are provided, and statistical analyses are insufficient."
        },
        "evidence_strength": "N/A"
      }
    },
    {
      "variant": "LRRK2 R1441C",
      "steps": {
        "step1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links R1441C to Parkinson's disease and its role in MAPK pathway dysfunction."
        },
        "step2": {
          "judgment": "Yes",
          "reason": "The assay (cell viability under oxidative stress) directly models the disease mechanism (oxidative stress and MAPK pathway dysfunction)."
        },
        "step3a": {
          "judgment": "No",
          "reason": "While wild-type (normal) and mutant (abnormal) controls are used, the paper does not explicitly mention replicates or statistical validation of results."
        },
        "step3b": {
          "judgment": "No",
          "reason": "The paper does not cite prior validation of the assay (e.g., no references to established methods) or mention commercial kits. The assay is not explicitly labeled as 'standard' in the literature."
        },
        "step3c": {
          "judgment": "No",
          "reason": "No known pathogenic/benign variants are explicitly used as controls in the study."
        },
        "step4a": {
          "judgment": "No",
          "reason": "No OddsPath values or statistical analyses (e.g., p-values, confidence intervals) are reported for R1441C."
        },
        "step4b": {
          "judgment": "No",
          "reason": "The study does not quantify the number of benign/pathogenic controls used, making it impossible to assess strength."
        },
        "step4c": {
          "judgment": "N/A",
          "reason": "No OddsPath values are provided, and statistical analyses are insufficient."
        },
        "evidence_strength": "N/A"
      }
    }
  ]
}